← All trials
NCT06795191
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2025
- Primary completion
- Nov 30, 2027
- Completion date
- Jan 2, 2028
- First posted
- Jan 27, 2025
- Last posted
- Apr 27, 2025
- Enrollment
- 0
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Foresee Pharmaceuticals Co., Ltd.Lead sponsor
- QPSCollaborator
- Foresee Pharmaceuticals Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.